How safe are heartburn medications and who should use them?

References

• Vakil N, van Zanten SV, Kahrilas P, et al.; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–1920.
   PubMed Web of Science ®Google Scholar
• Savarino E, Bazzica M, Zentilin P, et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using Ph-impedance monitoring. Am J Respir Crit Care Med. 2009;179(5):408–413. doi: 10.1164/rccm.200808-1359OC
   PubMed Web of Science ®Google Scholar
• Savarino E, Carbone R, Marabotto E, et al. Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur Respir J. 2013;42(5):1322–1331. doi: 10.1183/09031936.00101212
   PubMed Web of Science ®Google Scholar
• Savarino E, de Bortoli N, De Cassan C, et al. The natural history of gastro-esophageal reflux disease: a comprehensive review. Dis Esophagus. 2017;30(2):1–9. doi: 10.1111/dote.12511
   PubMed Web of Science ®Google Scholar
• Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease–current concepts and dilemmas. Am J Gastroenterol. 2001;96(2):303–314. doi: 10.1111/j.1572-0241.2001.03511.x
   PubMed Web of Science ®Google Scholar
• Fass R, Naliboff B, Higa L, et al. Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology. 1998;115(6):1363–1373. doi: 10.1016/S0016-5085(98)70014-9
   PubMed Web of Science ®Google Scholar
• Meyer JH, Lembo A, Elashoff JD, et al. Duodenal fat intensifies the perception of heartburn. Gut. 2001;49(5):624–628. doi: 10.1136/gut.49.5.624
   PubMed Web of Science ®Google Scholar
• Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut. 2002;51(6):885–892. doi: 10.1136/gut.51.6.885
   PubMed Web of Science ®Google Scholar
• van Pinxteren B, Numans ME, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2004;4:CD002095.
   Google Scholar
• Eusebi LH, Ratnakumaran R, Yuan Y, et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67(3):430–440. doi: 10.1136/gutjnl-2016-313589
   PubMed Web of Science ®Google Scholar
• Sigterman KE, van Pinxteren B, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;2013(5):CD002095. doi: 10.1002/14651858.CD002095.pub5
   PubMedGoogle Scholar
• Fass R, Solomon CG. Gastroesophageal reflux disease. N Engl J Med. 2022;387(13):1207–1216. doi: 10.1056/NEJMcp2114026
   PubMed Web of Science ®Google Scholar
• Zentilin P, Dulbecco P, Savarino E, et al. An evaluation of the antireflux properties of sodium alginate by means of combined multichannel intraluminal impedance and Ph-metry. Aliment Pharmacol Ther. 2005;21(1):29–34. doi: 10.1111/j.1365-2036.2004.02298.x
   PubMed Web of Science ®Google Scholar
• Kwiatek MA, Roman S, Fareeduddin A, et al. An alginate-antacid formulation (Gaviscon double action liquid) can eliminate or displace the postprandial ‘acid pocket’ in symptomatic GERD patients. Aliment Pharmacol Ther. 2011;34(1):59–66. doi: 10.1111/j.1365-2036.2011.04678.x
   PubMed Web of Science ®Google Scholar
• Woodland P, Lee C, Duraisamy Y, et al. Assessment and protection of esophageal mucosal integrity in patients with heartburn without esophagitis. Am J Gastroenterol. 2013;108(4):535–543. doi: 10.1038/ajg.2012.469
   PubMed Web of Science ®Google Scholar
• Giannini EG, Zentilin P, Dulbecco P, et al. A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms. Dig Dis Sci. 2006;51(11):1904–1909. doi: 10.1007/s10620-006-9284-0
   PubMed Web of Science ®Google Scholar
• Leiman DA, Riff BP, Morgan S, et al. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. Dis Esophagus. 2017;30(5):1–9. doi: 10.1093/dote/dow020
   Web of Science ®Google Scholar
• Chiu CT, Hsu CM, Wang CC, et al. Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease. Aliment Pharmacol Ther. 2013;38(9):1054–1064. doi: 10.1111/apt.12482
   PubMed Web of Science ®Google Scholar
• Reimer C, Lødrup AB, Smith G, et al. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor. Aliment Pharmacol Ther. 2016;43(8):899–909. doi: 10.1111/apt.13567
   PubMed Web of Science ®Google Scholar
• Surdea-Blaga T, Băncilă I, Dobru D, et al. Mucosal protective compounds in the treatment of gastroesophageal reflux disease. A position paper based on evidence of the romanian society of neurogastroenterology. J Gastrointestin Liver Dis. 2016;25(4):537–546. doi: 10.15403/jgld.2014.1121.254.dea
   PubMed Web of Science ®Google Scholar
• Di Simone MP, Baldi F, Vasina V, et al. Barrier effect of Esoxx(®) on esophageal mucosal damage: experimental study on ex-vivo swine model. Clin Exp Gastroenterol. 2012;5:103–107. doi: 10.2147/CEG.S31404
   PubMedGoogle Scholar
• Savarino V, Pace F, Scarpignato C, et al. Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease - efficacy of Esoxx, a hyaluronic acid-chondroitin sulphate based bioadhesive formulation. Aliment Pharmacol Ther. 2017;45(5):631–642. doi: 10.1111/apt.13914
   PubMed Web of Science ®Google Scholar
• Savarino V, Mela GS, Zentilin P, et al. Comparison of the effects of placebo, ranitidine, famotidine and nizatidine on intragastric acidity by means of continuous pH recording. Digestion. 1989;42(1):1–6. doi: 10.1159/000199818
   PubMed Web of Science ®Google Scholar
• Fass R, Boeckxstaens GE, El-Serag H, et al. Gastro-oesophageal reflux disease. Nat Rev Dis Primers. 2021;7(1):55. doi: 10.1038/s41572-021-00287-w
   PubMed Web of Science ®Google Scholar
• Savarino V, Mela GS, Zentilin P, et al. Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer. Aliment Pharmacol Ther. 1998;12(12):1241–1247. doi: 10.1046/j.1365-2036.1998.00416.x
   PubMed Web of Science ®Google Scholar
• Wilder-Smith CH, Ernst T, Gennoni M, et al. Tolerance to oral H2-receptor antagonists. Dig Dis Sci. 1990;35(8):976–983. doi: 10.1007/BF01537246
   PubMed Web of Science ®Google Scholar
• Vela MF, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology. 2001;120(7):1599–1606. doi: 10.1053/gast.2001.24840
   PubMed Web of Science ®Google Scholar
• Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD an overview of their pharmacology, efficacy and safety. Pharmacol Res. 2009;59(3):135–153. doi: 10.1016/j.phrs.2008.09.016
   PubMed Web of Science ®Google Scholar
• Savarino E, Zentilin P, Marabotto E, et al. A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD). Expert Opin Pharmacother. 2017;18(13):1333–1343. doi: 10.1080/14656566.2017.1361407
   PubMed Web of Science ®Google Scholar
• Savarino V, Marabotto E, Zentilin P, et al. Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease. Expert Rev Clin Pharmacol. 2020;13(4):437–449. doi: 10.1080/17512433.2020.1752664
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy Male Japanese/non-Japanese subjects. Clin Transl Gastroenterol. 2015;6(6):e94. doi: 10.1038/ctg.2015.18
   PubMedGoogle Scholar
• Savarino E, Martinucci I, Furnari M, et al. Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations. Expert Opin Drug Metab Toxicol. 2016;12(11):1333–1341. doi: 10.1080/17425255.2016.1214714
   PubMed Web of Science ®Google Scholar
• Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43(2):240–251. doi: 10.1111/apt.13461
   PubMed Web of Science ®Google Scholar
• Xiao Y, Zhang S, Dai N, et al. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut. 2020;69(2):224–230. doi: 10.1136/gutjnl-2019-318365
   PubMed Web of Science ®Google Scholar
• Kinoshita Y, Sakurai Y, Takabayashi N, et al. Efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a randomized, placebo-controlled, phase 3 study. Clin Transl Gastroenterol. 2019;10(11):e00101. doi: 10.14309/ctg.0000000000000101
   PubMedGoogle Scholar
• Savarino V, Marabotto E, Zentilin P, et al. Pharmacological management of gastro-esophageal reflux disease: an update of the state-of-the-art. Drug Des Devel Ther. 2021;15:1609–1621. doi: 10.2147/DDDT.S306371
   PubMed Web of Science ®Google Scholar
• Vela MF, Tutuian R, Katz PO, et al. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther. 2003;17(2):243–251. doi: 10.1046/j.1365-2036.2003.01394.x
   PubMed Web of Science ®Google Scholar
• Shi G, Bruley des Varannes S, Scarpignato C, et al. Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut. 1995;37(4):457–464. doi: 10.1136/gut.37.4.457
   PubMed Web of Science ®Google Scholar
• Savarino V, Marabotto E, Zentilin P, et al. Esophageal reflux hypersensitivity: non-GERD or still GERD?. Digestive Liver Dis. 2020;52(12):1413–1420. doi: 10.1016/j.dld.2020.10.003
   Web of Science ®Google Scholar
• Pouchain D, Bigard MA, Liard F, et al. Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial. BMC Gastroenterol. 2012;12(1):18. doi: 10.1186/1471-230X-12-18
   PubMedGoogle Scholar
• Savarino V, Dulbecco P, de Bortoli N, et al. The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. Eur J Intern Med. 2017;37:19–24.
   PubMed Web of Science ®Google Scholar
• Savarino V, Marabotto E, Zentilin P, et al. Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev Clin Pharmacol. 2018;11(11):1123–1134. doi: 10.1080/17512433.2018.1531703
   PubMed Web of Science ®Google Scholar
• Müller EE, Locatelli V, Cella S, et al. Prolactin-lowering and -releasing drugs. Mechanisms of action and therapeutic applications. Drugs. 1983;25(4):399–432. doi: 10.2165/00003495-198325040-00004
   PubMed Web of Science ®Google Scholar
• Savarino V, Giusti M, Scalabrini P, et al. Famotidine has no significant effect on gonadal function in man. Gastroenterol Clin Biol. 1988;12(1):19–22.
   PubMedGoogle Scholar
• Savarino V, Dulbecco P, Savarino E. Are proton pump inhibitors really so dangerous? Dig Liver Dis. 2016;48(8):851–859. doi: 10.1016/j.dld.2016.05.018
   PubMedGoogle Scholar
• Reimer C. Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol. 2013;27(3):443–454. doi: 10.1016/j.bpg.2013.06.001
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14(12):697–710. doi: 10.1038/nrgastro.2017.117
   PubMed Web of Science ®Google Scholar
• Savarino E, Marabotto E, Zentilin P, et al. A safety review of proton pump inhibitors to treat acid-related digestive diseases. Expert Opin Drug Saf. 2018;17(8):785–794. doi: 10.1080/14740338.2018.1497155
   PubMed Web of Science ®Google Scholar
• Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011;56(4):931–950. doi: 10.1007/s10620-010-1560-3
   PubMed Web of Science ®Google Scholar
• Leiman DA, Ravi K, Freedberg DE, et al. Proton pump inhibitor prescribing and monitoring patterns among gastroenterology practitioners. J Clin Gastroenterol. 2022;56(7):571–575. doi: 10.1097/MCG.0000000000001623
   PubMed Web of Science ®Google Scholar
• Savarino V, Marabotto E, Furnari M, et al. Latest insights into the hot question of proton pump inhibitor safety - a narrative review. Dig Liver Dis. 2020;52(8):842–852. doi: 10.1016/j.dld.2020.04.020
   PubMedGoogle Scholar
• Haga Y, Nakatsura T, Shibata Y, et al. Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor. Dig Dis Sci. 1998;43(2):253–257. doi: 10.1023/A:1018881617038
   PubMed Web of Science ®Google Scholar
• Tran-Duy A, Spaetgens B, Hoes AW, et al. Use of proton pump inhibitors and risks of fundic gland polyps and gastric cancer: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(12):1706–1719.e5. doi: 10.1016/j.cgh.2016.05.018
   PubMed Web of Science ®Google Scholar
• Piovani D, Tsantes AG, Schünemann HJ, et al. Meta-analysis: use of proton pump inhibitors and risk of gastric cancer in patients requiring gastric acid suppression. Aliment Pharmacol Ther. 2023;57(6):653–665. doi: 10.1111/apt.17360
   PubMed Web of Science ®Google Scholar
• Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152(4):706–715. doi: 10.1053/j.gastro.2017.01.031
   PubMed Web of Science ®Google Scholar
• Savarino V, Tosetti C, Benedetto E, et al. Appropriateness in prescribing PPIs: a position paper of the Italian Society of Gastroenterology (SIGE) - study section “DIgestive Diseases In Primary Care”. Dig Liver Dis. 2018;50(9):894–902. doi: 10.1016/j.dld.2018.07.004
   PubMedGoogle Scholar
• Sun Y, Yue L, Hu W. Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials. Eur J Clin Pharmacol. 2023;79(2):279–288. doi: 10.1007/s00228-022-03430-y
   PubMed Web of Science ®Google Scholar
• Ashida K, Iwakiri K, Hiramatsu N, et al. Maintenance for healed erosive esophagitis:phase III comparison of vonoprazan with lansoprazole. World J Gastroenterol. 2018;24(14):1550–1561. doi: 10.3748/wjg.v24.i14.1550
   PubMed Web of Science ®Google Scholar
• Yang M, Ren C, Yang Z. Vonoprazan may induce clostridium difficile infection and nephrotoxicity. Gastroenterology. 2023;164(4):699. doi: 10.1053/j.gastro.2022.10.004
   PubMed Web of Science ®Google Scholar
• Giudicessi JR, Ackerman MJ, Camilleri M. Cardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias. Neurogastroenterol Motil. 2018;30(6):e13302. doi: 10.1111/nmo.13302
   PubMed Web of Science ®Google Scholar
• Cowan A, Garg AX, McArthur E, et al. Cardiovascular safety of metoclopramide compared to domperidone: a population-based cohort study. J Can Assoc Gastroenterol. 2020 Dec 18;4(5):e110–e119. doi: 10.1093/jcag/gwaa041
   PubMedGoogle Scholar
• Tack J, Derakhchan K, Gabriel A, et al. A review of the cardiovascular safety of prucalopride in patients with chronic idiopathic constipation. Am J Gastroenterol. 2023;118(6):955–960. Epub ahead of print. PMID: 36927957. doi: 10.14309/ajg.0000000000002249
   PubMed Web of Science ®Google Scholar
• Wise J, Conklin JL. Gastroesophageal reflux disease and baclofen: is there a light at the end of the tunnel? Curr Gastroenterol Rep. 2004;6(3):213–219. doi: 10.1007/s11894-004-0010-9
   PubMedGoogle Scholar
• Limsrivilai J, Charatcharoenwitthaya P, Pausawasdi N, et al. Imipramine for treatment of esophageal hypersensitivity and functional heartburn: a randomized placebo-controlled trial. Am J Gastroenterol. 2016;111(2):217–224. doi: 10.1038/ajg.2015.413
   PubMed Web of Science ®Google Scholar
• Jackson WK, Roose SP, Glassman AH. Cardiovascular toxicity and tricyclic antidepressants. Biomed Pharmacother. 1987;41(7):377–382.
   PubMed Web of Science ®Google Scholar
• Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatry. 1999;60(Suppl 4):4–11. discussion 12-3. doi: 10.4088/JCP.v60n1204
   PubMed Web of Science ®Google Scholar
• Viazis N, Keyoglou A, Kanellopoulos AK, et al. Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol. 2012;107(11):1662–1667. doi: 10.1038/ajg.2011.179
   PubMed Web of Science ®Google Scholar
• Ostovaneh MR, Saeidi B, Hajifathalian K, et al. Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: double-blind placebo-controlled trial. Neurogastroenterol Motil. 2014;26(5):670–678. doi: 10.1111/nmo.12313
   PubMed Web of Science ®Google Scholar
• Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano-Monghidoro study. Gut. 2008;57(10):1354–1359. doi: 10.1136/gut.2007.145177
   PubMed Web of Science ®Google Scholar
• Savarino E, Zentilin P, Savarino V. NERD: an umbrella term including heterogeneous subpopulations. Nat Rev Gastroenterol Hepatol. 2013;10(6):371–380. doi: 10.1038/nrgastro.2013.50
   PubMed Web of Science ®Google Scholar
• Shah A, Shibli F, Kitayama Y, et al. The natural course of gastroesophageal reflux disease: a critical appraisal of the literature. J Clin Gastroenterol. 2021;55(1):12–20. doi: 10.1097/MCG.0000000000001419
   PubMed Web of Science ®Google Scholar
• Fiocca R, Mastracci L, Milione M, et al. Gruppo Italiano Patologi Apparato Digerente (GIPAD); Società Italiana di Anatomia Patologica e Citopatologia Diagnostica/International Academy of Pathology, Italian division (SIAPEC/IAP). Microscopic esophagitis and Barrett’s esophagus: the histology report. Dig Liver Dis. 2011;43 Suppl 4:S319–S330. doi: 10.1016/S1590-8658(11)60588-4
   PubMedGoogle Scholar
• Savarino E, Frazzoni M, Marabotto E, et al. A SIGE-SINGEM-AIGO technical review on the clinical use of esophageal reflux monitoring. Dig Liver Dis. 2020;52(9):966–980. doi: 10.1016/j.dld.2020.04.031
   PubMedGoogle Scholar
• Yang M, Li ZS, Chen DF, et al. Quantitative assessment and characterization of visceral hyperalgesia evoked by esophageal balloon distention and acid perfusion in patients with functional heartburn, nonerosive reflux disease, and erosive esophagitis. Clin J Pain. 2010;26(4):326–331. doi: 10.1097/AJP.0b013e3181c8fc83
   PubMed Web of Science ®Google Scholar
• Savarino E, Zentilin P, Tutuian R, et al. The role of nonacid reflux in NERD: lessons learned from impedance-Ph monitoring in 150 patients off therapy. Am J Gastroenterol. 2008;103(11):2685–2693. doi: 10.1111/j.1572-0241.2008.02119.x
   PubMed Web of Science ®Google Scholar
• Patel D, Fass R, Vaezi M. Untangling nonerosive reflux disease from functional heartburn. Clin Gastroenterol Hepatol. 2021;19(7):1314–1326. doi: 10.1016/j.cgh.2020.03.057
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Bredenoord AJ, Cheng E, et al. PPI-REE task force of the European Society of Eosinophilic Oesophagitis (EUREOS). Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut. 2016;65(3):524–531. doi: 10.1136/gutjnl-2015-310991
   PubMed Web of Science ®Google Scholar
• Savarino EV, Tolone S, Bartolo O, et al. The GerdQ questionnaire and high resolution manometry support the hypothesis that proton pump inhibitor-responsive oesophageal eosinophilia is a GERD-related phenomenon. Aliment Pharmacol Ther. 2016;44(5):522–530. doi: 10.1111/apt.13718
   PubMed Web of Science ®Google Scholar
• Sifrim D, Fornari F. Esophageal impedance-Ph monitoring. Dig Liver Dis. 2008;40(3):161–166. doi: 10.1016/j.dld.2007.10.023
   PubMedGoogle Scholar
• de Bortoli N, Penagini R, Savarino E, et al. Eosinophilic esophagitis: update in diagnosis and management. Position paper by the Italian Society of Gastroenterology and Gastrointestinal Endoscopy (SIGE). Dig Liver Dis. 2017;49(3):254–260. doi: 10.1016/j.dld.2016.11.012
   PubMedGoogle Scholar
• Aziz Q, Fass R, Gyawali CP, et al. Functional Esophageal Disorders. Gastroenterology. 2016:S0016-5085(16)00178–5. doi: 10.1053/j.gastro.2016.02.012
   Google Scholar
• Savarino E, Marabotto E, Savarino V. Recent insights on functional heartburn and reflux hypersensitivity. Curr Opin Gastroenterol. 2022;38(4):417–422. doi: 10.1097/MOG.0000000000000846
   PubMed Web of Science ®Google Scholar
• Savarino E, Zentilin P, Mastracci L, et al. Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. J Gastroenterol. 2013;48(4):473–482. doi: 10.1007/s00535-012-0672-2
   PubMed Web of Science ®Google Scholar
• Savarino E, Zentilin P, Tutuian R, et al. Impedance-Ph reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients. J Gastroenterol. 2012;47(2):159–168. doi: 10.1007/s00535-011-0480-0
   PubMed Web of Science ®Google Scholar
• Martinucci I, de Bortoli N, Savarino E, et al. Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn. Neurogastroenterol Motil. 2014 Apr;26(4):546–555. Epub 2014 Jan 17. PMID: 24433456. doi: 10.1111/nmo.12299
   PubMed Web of Science ®Google Scholar
• Mainie I, Tutuian R, Agrawal A, et al. Combined multichannel intraluminal impedance-Ph monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication. Br J Surg. 2006;93(12):1483–1487. doi: 10.1002/bjs.5493
   PubMed Web of Science ®Google Scholar
• Broeders JA, Draaisma WA, Bredenoord AJ, et al. Oesophageal acid hypersensitivity is not a contraindication to Nissen fundoplication. Br J Surg. 2009;96(9):1023–1030. doi: 10.1002/bjs.6684
   PubMed Web of Science ®Google Scholar
• Spechler SJ, Hunter JG, Jones KM, et al. Randomized trial of medical versus surgical treatment for refractory heartburn. N Engl J Med. 2019;381(16):1513–1523. doi: 10.1056/NEJMoa1811424
   PubMed Web of Science ®Google Scholar
• Sawada A, Guzman M, Nikaki K, et al. Identification of different phenotypes of esophageal reflux hypersensitivity and implications for treatment. Clin Gastroenterol Hepatol. 2021;19(4):690–8.e2. doi: 10.1016/j.cgh.2020.03.063
   PubMed Web of Science ®Google Scholar
• Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol. 1997;32(10):965–973. doi: 10.3109/00365529709011211
   PubMed Web of Science ®Google Scholar
• Scarpignato C, Gatta L, Zullo A, et al.; SIF-AIGO-FIMMG Group. Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - a position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179. doi: 10.1186/s12916-016-0718-z
   PubMedGoogle Scholar
• Savarino V, Marabotto E, Zentilin P, et al. The appropriate use of proton-pump inhibitors. Minerva Med. 2018;109(5):386–399. doi: 10.23736/S0026-4806.18.05705-1
   PubMed Web of Science ®Google Scholar
• Salvo EM, Ferko NC, Cash SB, et al. Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors. Aliment Pharmacol Ther. 2021;54(2):129–143. doi: 10.1111/apt.16407
   PubMed Web of Science ®Google Scholar